Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B. Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above. Phase III BASIS trial supported Hympavzi approval, showing a 93% reduction in bleeding rate versus on-demand intravenous agents. Credit: Sai Thaw Kyar / Shutterstock.com. Pfizer has received approval from the US Food and Drug Administration (FDA) for an expanded indication of Hympavzi (marstacimab-hncq) for the treatment of haemophilia A or B. The approval covers patients aged 12 years and older with inhibitors,…

Source: Pharmaceutical Technology